Novartis' breast cancer treatment wins FDA approval

The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland January 25, 2017. REUTERS/Arnd Wiegmann

(Reuters) – The U.S. Food and Drug Administration (FDA) said on Friday it approved Novartis AG’s treatment in combination with hormone therapy fulvestrant for postmenopausal women, as well as men, with a form of advanced breast cancer.

The drug, alpelisib, to be marketed with the brand name Piqray, belongs to a class of drugs known as PI3K inhibitors and is the first of its kind to be approved, the FDA said in a statement.

Reporting by Manojna Maddipatla in Bengaluru; Editing by Anil D’Silva


READ  ‘We’re concerned but calm’: five voices from the frontline against Covid-19

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.